Wayne Eskridge describes some of the opportunities and concerns that affect diabetic patients might experience as they learn about NASH and the liver issues related to diabetes.
Jörn Schattenberg reviews modes of action for GLP-1 agonists and SGLT-2 inhibitors and discusses the data that exist in NAFLD and NASH
Jörn Schattenberg and Fatty Liver Foundation President Wayne Eskridge join Louise and Roger to consider the current and future roles that GLP-1 receptor agonists like semaglutide and SGLT-2 inhibitors like Jardiance in treating NASH patients.
The Surfers and guests Manal Abdelmalek, Naim Alkhouri, and Akero Therapeutics Chief Development Officer Kitty Yale share high-level perspectives on the FDA Webcast, both before and after the group’s detailed conversation
Manal Abdelmalek joins the Surfers to discuss key themes they hope to hear at the January 29 FDA Webcast on NASH Drug Development
Manal Abdelmalek joins the Surfers to discuss key themes they hope to hear at the January 29 FDA Webcast on NASH Drug Development
Manal Abdelmalek, Naim Alkhouri and Akero Therapeutics Chief Development Officer Kitty Yale join the Surfers to discuss Friday’s FDA webcast on NASH Drug Development.
Manal Abdelmalek joins the Surfers to share expectations in advance of Friday’s FDA Webcast on NASH Drug Development
Wayne Eskridge describes how hope fell and then rose as patients did not receive the drug approval they expected but then learned about exciting paths for new agents and non-invasive testing
Guests Ian Rowe, Joern Schattenberg and Wayne Eskridge join the Surfers to discuss key lessons learned in 2020 about Patient Treatment and Perspectives
